Home >> Signaling Pathways >> Tyrosine Kinase

Tyrosine Kinase

Products for  Tyrosine Kinase

  1. Cat.No. Product Name Information
  2. GC17283 AP26113 AP26113 (Brigatinib analog) is a potent and selective active inhibitor of anaplastic lymphoma kinase(ALK), Patent US20140066406 A1. AP26113  Chemical Structure
  3. GC14292 Apatinib Mesylate

    Apatinib blocks the downstream signal transduction of VEGF pathway to inhibit neovascularization.

    Apatinib Mesylate  Chemical Structure
  4. GC49799 Apatinib-d8 An internal standard for the quantification of apatinib Apatinib-d8  Chemical Structure
  5. GC65515 Aprutumab Aprutumab?(BAY 1179470) is a fully human FGFR2 monoclonal antibody, which binds to the FGFR2 isoforms FGFR2-IIIb and FGFR2-IIIc. Aprutumab has?the?potential?for?solid tumors research. Aprutumab  Chemical Structure
  6. GC12478 ARRY-380 ARRY-380, an inhibitor of EGFR (ErbB1), is extracted from patent WO2015153959A2, compound 249. ARRY-380 is a potent, selective, ATP-competitive, orally active inhibitor of HER2. ARRY-380  Chemical Structure
  7. GC46013 AS-2444697 (hydrochloride) AS-2444697 (hydrochloride) is an orally active IRAK-4 inhibitor with an IC50 of 21 nM. AS-2444697 (hydrochloride)  Chemical Structure
  8. GC32703 Asciminib (ABL001) Asciminib (ABL001) (ABL001) is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Asciminib (ABL001)  Chemical Structure
  9. GC64462 Asciminib hydrochloride Asciminib (ABL001) hydrochloride is a potent and selective allosteric BCR-ABL1 inhibitor, which inhibits Ba/F3 cells grown with an IC50 of 0.25 nM. Asciminib hydrochloride  Chemical Structure
  10. GC62402 ASK120067 ASK120067 (ASK120067) is a potent and orally active inhibitor of EGFRT790M (IC50:0.3 nM) with selectivity over EGFRWT (IC50:6.0 nM). ASK120067 is a third-generation EGFR-TKI for the research ofnon-small cell lung cancer (NSCLC). ASK120067  Chemical Structure
  11. GC14446 ASP3026 An ALK inhibitor ASP3026  Chemical Structure
  12. GC34476 ASP5878 ASP5878 is an oral active inhibitor of FGFR 1, 2, 3, and 4, with IC50 values of 0.47 nM, 0.6 nM, 0.74 nM and 3.5 nM for FGFR 1, 2, 3, and 4 kinase activity. ASP5878 has potential antineoplastic activity. ASP5878  Chemical Structure
  13. GC10914 AST 487 A multi-kinase inhibitor AST 487  Chemical Structure
  14. GC11691 AST-1306 AST-1306 (AST-1306) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 is an anilino-quinazoline compound and has anti-cancer activity. AST-1306  Chemical Structure
  15. GC15669 AST-1306 TsOH AST-1306 TsOH (AST-1306 (TsOH)) is an orally active and irreversible EGFR and ErbB2 inhibitor with IC50s of 0.5 and 3 nM, respectively. AST-1306 TsOH also inhibits ErbB4 with an IC50 of 0.8 nM. AST-1306 TsOH is an anilino-quinazoline compound and has anti-cancer activity AST-1306 TsOH  Chemical Structure
  16. GC33096 AST2818 mesylate Alflutinib (Furmonertinib) mesylate is is a potent inhibitor of EGFR. Alflutinib (Furmonertinib) mesylate inhibits EGFR active mutations as well as the T790M acquired resistant mutation. Alflutinib (Furmonertinib) mesylate has the potential for the research of cancer diseases, especially non-small cell lung cancer (NSCLC). AST2818 mesylate  Chemical Structure
  17. GC62481 AST5902 trimesylate AST5902 trimesylate is the principal metabolite of Alflutinib (AST2818) both in vitro and in vivo. AST5902 trimesylate exerts antineoplastic activity. Alflutinib is an EGFR inhibitor. AST5902 trimesylate  Chemical Structure
  18. GC35413 Astragaloside VI Astragaloside VI could activate EGFR/ERK signalling pathway to improve wound healing. Astragaloside VI  Chemical Structure
  19. GC10638 AT9283 A broad spectrum kinase inhibitor AT9283  Chemical Structure
  20. GC62499 ATH686 ATH686 is a potent, selective and ATP-competitive FLT3 inhibitor. ATH686 target mutant FLT3 protein kinase activity and inhibit the proliferation of cells harboring FLT3 mutants via induction of apoptosis and cell cycle inhibition. ATH686 has antileukemic effects. ATH686  Chemical Structure
  21. GC35435 AV-412 A dual inhibitor of EGFR and HER2 AV-412  Chemical Structure
  22. GC35436 AV-412 free base AV-412 free base (MP-412 free base) is an EGFR inhibitor with IC50s of 0.75, 0.5, 0.79, 2.3, 19 nM for EGFR, EGFRL858R, EGFRT790M, EGFRL858R/T790M and ErbB2, respectively. AV-412 free base  Chemical Structure
  23. GC19074 Avapritinib Avapritinib is a potent and selective exon 17 mutant KIT kinase inhibitor with IC50 of 0.27 nM for KIT D816V. Avapritinib  Chemical Structure
  24. GC42884 Avitinib

    Avitinib is a pyrrolopyrimidine-based, irreversible inhibitor of the epidermal growth factor receptor (EGFR).

    Avitinib  Chemical Structure
  25. GC19044 Avitinib maleate

    A pyrrolopyrimidine-based irreversible EGFR inhibitor

    Avitinib maleate  Chemical Structure
  26. GC64683 AVJ16 AVJ16 is a member of the insulin-like growth factor 2 mRNA-binding protein family. AVJ16 regulates protein translation by binding to the mRNAs of certain genes. AVJ16  Chemical Structure
  27. GC12216 Axitinib (AG 013736) Axitinib (AG 013736) is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively. Axitinib (AG 013736)  Chemical Structure
  28. GC42887 Axitinib Sulfoxide Axitinib sulfoxide is a major inactive metabolite of the tyrosine kinase inhibitor axitinib. Axitinib Sulfoxide  Chemical Structure
  29. GC46899 Axitinib-13C-d3 An internal standard for the quantification of axitinib Axitinib-13C-d3  Chemical Structure
  30. GC62185 Axitinib-d3 Axitinib-d3 (AG-013736-d3) is deuterium labeled Axitinib. Axitinib is a multi-targeted tyrosine kinase inhibitor with IC50s of 0.1, 0.2, 0.1-0.3, 1.6 nM for VEGFR1, VEGFR2, VEGFR3 and PDGFRβ, respectively. Axitinib-d3  Chemical Structure
  31. GC17045 AXL1717 A potent and selective inhibitor of IGF-1R AXL1717  Chemical Structure
  32. GC50221 AZ Dyrk1B 33 Potent and selective Dyrk1B kinase inhibitor AZ Dyrk1B 33  Chemical Structure
  33. GC33090 AZ-23 (AZ23) AZ-23 (AZ23) is an ATP-competitive and orally bioavailable Trk kinase A/B/C inhibitor with IC50s of 2 nM (TrkA), 8 nM (TrkB), 24 nM (FGFR1), 52 nM (Flt3), 55 nM (Ret), 84 nM (MuSk), 99 nM (Lck), respectively. AZ-23 (AZ23)  Chemical Structure
  34. GC64071 AZ14145845 AZ14145845 is a highly selective type I1/2 dual Mer/Axl kinase inhibitor with in vivo efficacy. AZ14145845  Chemical Structure
  35. GC33054 AZ1495 An oral active inhibitor of IRAK4 AZ1495  Chemical Structure
  36. GC17654 AZ191 DYRK1B inhibitor,potent and selective AZ191  Chemical Structure
  37. GC12955 AZ5104 EGFR inhibitor AZ5104  Chemical Structure
  38. GC33072 AZ7550 AZ7550 is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM. AZ7550  Chemical Structure
  39. GC34287 AZ7550 hydrochloride AZ7550 hydrochloride is an active metabolite of AZD9291 and inhibits the activity of IGF1R with an IC50 of 1.6 μM. AZ7550 hydrochloride  Chemical Structure
  40. GC34414 AZ7550 Mesylate (AZ7550 trimesylate salt) AZ7550 Mesylate (AZ7550 trimesylate salt)  Chemical Structure
  41. GC31880 AZD-0284 AZD-0284 is a selective inverse agonist of the nuclear receptor RORγ. AZD-0284  Chemical Structure
  42. GC14189 AZD-3463 ALK/IGF1R inhibitor AZD-3463  Chemical Structure
  43. GC16308 AZD-9291 AZD-9291 (AZD9291) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M, respectively. AZD-9291 overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. AZD-9291  Chemical Structure
  44. GC16698 AZD-9291 mesylate AZD-9291 mesylate (AZD9291 mesylate) is a covalent, orally active, irreversible, and mutant-selective EGFR inhibitor with an apparent IC50 of 12 nM against L858R and 1 nM against L858R/T790M. Osimertinib overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. AZD-9291 mesylate  Chemical Structure
  45. GC17959 AZD2932 inhibitor of VEGFR-2, PDGFRβ, Flt-3, and c-Kit AZD2932  Chemical Structure
  46. GC33027 AZD3229 An inhibitor of c-Kit-driven cell proliferation AZD3229  Chemical Structure
  47. GC33246 AZD3229 Tosylate AZD3229 Tosylate is a potent pan-KIT mutant inhibitor for the treatment of gastrointestinal stromal tumors. AZD3229 Tosylate  Chemical Structure
  48. GC13143 AZD3759 AZD3759 (AZD3759) is a potent, orally active, central nervous system-penetrant, EGFR inhibitor. At Km ATP concentrations, the IC50s are 0.3, 0.2, and 0.2 nM for EGFRwt, EGFRL858R, and EGFRexon 19Del, respectively. AZD3759  Chemical Structure
  49. GC14005 AZD4547 FGFR inhibitor AZD4547  Chemical Structure
  50. GC19404 AZD7507

    AZD7507 is a potent and selective CSF-1R inhibitor (32 nM cell activity)

    AZD7507  Chemical Structure
  51. GC13761 AZD8931 (Sapitinib) AZD8931 (Sapitinib) (AZD-8931) is a reversible, ATP competitive EGFR inhibitor of with IC50s of 4, 3 and 4 nM for EGFR, ErbB2 and ErbB3 in cells, respectively. AZD8931 (Sapitinib)  Chemical Structure
  52. GC32875 AZM475271 (M475271) AZM475271 (M475271) is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2. AZM475271 (M475271)  Chemical Structure
  53. GC18580 B355252 A neuroprotective agent B355252  Chemical Structure
  54. GC35462 Bafetinib

    Bcr-Abl/Lyn tyrosine kinase inhibitor

    Bafetinib  Chemical Structure
  55. GC68727 Barzolvolimab

    Barzolvolimab (CDX 0159) is a humanized monoclonal antibody against KIT IgG1. Barzolvolimab specifically and effectively inhibits the activation of KIT. Barzolvolimab can reduce skin mast cells and disease activity in chronic inducible urticaria.

    Barzolvolimab  Chemical Structure
  56. GC64377 Batatasin III Batatasin III, a stilbenoid, inhibits cancer migration and invasion by suppressing epithelial to mesenchymal transition (EMT) and FAK-AKT signals. Batatasin III has anti-cancer activities. Batatasin III  Chemical Structure
  57. GC11726 BAW2881 (NVP-BAW2881) BAW2881 (NVP-BAW2881) (BAW2881) is a potent and selective VEGFR2 inhibitor with an IC50 of 4 nM. BAW2881 (NVP-BAW2881)  Chemical Structure
  58. GC64302 BAY 2476568 BAY 2476568 is a potent and selective EGFR inhibitor, with IC50s of < 0.2 nM for wild-type EGFR and several mutations (EGFRR ex20insSVD, EGFRR ex20insASV, EGFRR ex20insNPG). BAY 2476568  Chemical Structure
  59. GC16389 BAY 61-3606 A Syk inhibitor BAY 61-3606  Chemical Structure
  60. GC12136 BAY 61-3606 dihydrochloride BAY 61-3606 dihydrochloride  Chemical Structure
  61. GC19062 BBT594 BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment. BBT594  Chemical Structure
  62. GC33343 BCR-ABL-IN-1 BCR-ABL-IN-1 is an inhibitor of BCR-ABL tyrosine kinase, with a pIC50 of 6.46, and may be used in the research of chronic myelogenous leukemia. BCR-ABL-IN-1  Chemical Structure
  63. GC33368 BCR-ABL-IN-2 BCR-ABL-IN-2 is an inhibitor of BCR-ABL1 tyrosine kinase, with IC50s of 57 nM, 773 nm for ABL1native and ABL1T315I, respectively. BCR-ABL-IN-2  Chemical Structure
  64. GC12186 BDNF (human) activator of TrkB and p75 neurotrophin receptors BDNF (human)  Chemical Structure
  65. GC60629 BDTX-189 BDTX-189 (BDTX-189) is a potent, orally active and selective inhibitor of allosteric EGFR and HER2 oncogenic mutations, including EGFR/HER2 exon 20 insertion mutants. BDTX-189 shows KDs of 0.2, 0.76, 13 and 1.2 nM for EGFR, HER2, BLK and RIPK2, reapectively. Anticancer activity. BDTX-189  Chemical Structure
  66. GC64017 Befotertinib Befotertinib (D-0316) is the third-generation EGFR tyrosine kinase inhibitor. Befotertinib can be used for the research of EGFR T790M-positive non-small cell lung cancer (NSCLC). Befotertinib  Chemical Structure
  67. GC19063 Belizatinib Belizatinib is an oral, dual, potent inhibitor of ALK and TRKA, TRKB, and TRKC, with IC50 of 0.7 nM for wild-type recombinant ALK kinase. Belizatinib  Chemical Structure
  68. GC65516 Bemarituzumab Bemarituzumab is a first-in-class, humanized IgG1 monoclonal antibody against FGFR2b (a FGF receptor). Bemarituzumab blocks fibroblast growth factors from binding and activating FGFR2b. Bemarituzumab has the potential for cancer research. Bemarituzumab  Chemical Structure
  69. GC34216 Bevacizumab (Anti-Human VEGF, Humanized Antibody) Bevacizumab (Anti-Human VEGF, Humanized Antibody), a humanized IgG1 monoclonal antibody, specifically binds to all VEGF-A isoforms with high affinity. Bevacizumab (Anti-Human VEGF, Humanized Antibody)  Chemical Structure
  70. GC63436 Bevurogant Bevurogant is a retinoid-related orphan receptor-gamma t (RORγt) antagonist. Bevurogant  Chemical Structure
  71. GC64810 Bezuclastinib Bezuclastinib (CGT9486; PLX 9486) is a potent inhibitor of c-kit and c-kit D816V (0.0001 Bezuclastinib  Chemical Structure
  72. GC15340 BFH772 VEGFR2 inhibitor BFH772  Chemical Structure
  73. GC33172 BGB-102 (JNJ-26483327) BGB-102 (JNJ-26483327) is a potent multi-kinase inhibitor against EGFR, HER2, and HER4 with IC50s of 9.6 nM, 18 nM and 40.3 nM, respectively. BGB-102 (JNJ-26483327)  Chemical Structure
  74. GC19066 BGB-283 BGB-283 is a novel and potent Raf Kinase and EGFR inhibitor with IC50 values of 23 and 29 nM for recombinant BRafV600E and EGFR, respectively. BGB-283  Chemical Structure
  75. GC10055 BGJ398 An FGFR inhibitor BGJ398  Chemical Structure
  76. GC65457 BI-3663 BI-3663 is a highly selective PTK2/FAK PROTAC (DC50=30 nM), with Cereblon ligands to hijack E3 ligases for PTK2 degradation. BI-3663 inhibits PTK2 with an IC50 of 18 nM. BI-3663 is a PROTAC that composes of BI-4464 linked to Pomalidomide with a linker. Anti-cancer activity. BI-3663  Chemical Structure
  77. GC38402 BI-4020 A fourth-generation and non-covalent EGFR tyrosine kinase inhibitor BI-4020  Chemical Structure
  78. GC34488 BI-4464 BI-4464 is a highly selective ATP competitive inhibitor of PTK2/FAK, with an IC50 of 17 nM. A PTK2 ligand for PROTAC. BI-4464  Chemical Structure
  79. GC65886 BI-853520 BI 853520 (IN-10018) is an orally active and potent focal adhesion kinase (FAK) inhibitor (recombinant FAK IC50=1nM). BI 853520 shows anti-proliferative activity against cancer cells. BI-853520  Chemical Structure
  80. GC35516 BIBF 1202 BIBF 1202 is the carboxylate metabolite of BIBF 1120 which inhibits VEGFR2 kinase with an IC50 of 62 nM. BIBF 1202  Chemical Structure
  81. GC10815 BIBU 1361 dihydrochloride EGFR inhibitor BIBU 1361 dihydrochloride  Chemical Structure
  82. GC10087 BIBX 1382 An EGFR inhibitor BIBX 1382  Chemical Structure
  83. GC50026 BIBX 1382 dihydrochloride Highly selective EGFR-kinase inhibitor BIBX 1382 dihydrochloride  Chemical Structure
  84. GC19075 BLU-554 BLU-554 (BLU-554) is a potent, highly selective and orally active fibroblast growth factor receptor 4 (FGFR4) inhibitor with an IC50 of 5 nM. BLU-554 has significant anti-tumor activity in models of hepatocellular carcinoma (HCC) that are dependent on FGFR4 signalling. BLU-554  Chemical Structure
  85. GC63910 BLU-945 BLU-945 is a potent, highly selective, reversible and orally active epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKIs). BLU-945 can effectively inhibit EGFR with L858R and/or exon 19 deletion mutation, T790M mutation and C797S mutation. BLU-945 can be used for the research of lung cancer including non-small cell lung cancer (NSCLC). BLU-945  Chemical Structure
  86. GC10833 BLU9931 FGFR4 inhibitor,potent and irreversible BLU9931  Chemical Structure
  87. GC12539 BLZ945 BLZ945 (BLZ945) is a potent, selective and brain-penetrant CSF-1R (c-Fms) inhibitor with an IC50 of 1 nM, showing more than 1,000-fold selectivity against its closest receptor tyrosine kinase homologs. BLZ945  Chemical Structure
  88. GC14136 BMS 599626 dihydrochloride EGFR and ErbB2 inhibitor,potent and selective BMS 599626 dihydrochloride  Chemical Structure
  89. GC50330 BMS 605541 Potent VEGFR-2 inhibitor BMS 605541  Chemical Structure
  90. GC10455 BMS-509744 BMS-509744  Chemical Structure
  91. GC17773 BMS-536924

    IR/IGF-1R inhibitor

    BMS-536924  Chemical Structure
  92. GC10606 BMS-599626 Hydrochloride BMS-599626 Hydrochloride  Chemical Structure
  93. GC13873 BMS-690514 BMS-690514  Chemical Structure
  94. GC16712 BMS-754807 IGF-1R/InsR inhibitor,potent and selective BMS-754807  Chemical Structure
  95. GC14214 BMS-777607

    BMS-777607 is a pan-TAM inhibitor, which shows anti-tumor activity to different types of cancer.

    BMS-777607  Chemical Structure
  96. GC13833 BMS-794833 Met/VEGFR-2 inhibitor,potent and ATP-competitive BMS-794833  Chemical Structure
  97. GC17772 BMS-817378 Potent ATP competitive inhibitor of Met/VEGFR2 BMS-817378  Chemical Structure
  98. GC11063 BMX-IN-1 A selective BMX and BTK inhibitor BMX-IN-1  Chemical Structure
  99. GC13343 Bosutinib (SKI-606) Bosutinib (SKI-606) is an oral Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively. Bosutinib (SKI-606)  Chemical Structure
  100. GC40080 Bosutinib-d8 Bosutinib-d8 is intended for use as an internal standard for the quantification of bosutinib by GC- or LC-MS. Bosutinib-d8  Chemical Structure
  101. GC38894 Bozitinib Bozitinib (PLB-1001) is a highly selective c-MET kinase inhibitor with blood-brain barrier permeability. Bozitinib (PLB-1001) is a ATP-competitive small-molecule inhibitor, binds to the conventional ATP-binding pocket of the tyrosine kinase superfamily. Bozitinib  Chemical Structure

Items 101 to 200 of 1115 total

per page
  1. 1
  2. 2
  3. 3
  4. 4
  5. 5

Set Descending Direction